About This Course

An estimated number of 10.6 million people developed tuberculosis disease in 2022 leading to a total number of 1.3 million deaths including 167 000 people living with HIV. A major challenge remains diagnosis, in more than 50% of young children the diagnosis is missed. An exciting new development is the implementation of stool-based testing in children who cannot produce sputum and the use of other non-sputum samples in order to close the diagnostic gap. Computer-aided detection (CAD) presents an opportunity to improve the detection of TB particularly in hard-to reach populations by automating and standardizing X-ray interpretation. Many countries are using now promising new case-finding strategies.

There is also revolutionary progress regarding treatment duration: treatment duration of non-severe drug-sensitive as well as drug-resistant TB can be shortened to 4 months and 6 months respectively and also TB preventive therapy can be shortened significantly. Moreover, for the first time, we now have a new effective TB vaccine within reach.

This course will provide you with the most important epidemiological-, diagnostic-, preventive-, and therapeutic news including examples for new case-finding strategies based on the latest WHO guidelines and presentations during the November 2023 World TB conference.

The course was prepared by Dr. Clemens Richter, CME consultant AHF in cooperation with Dr.Adele Schwartz Benzaken, Senior Global Medical Director and Dr. Fernanda Fonseca, Associate Global Medical Director, and is awarded with 5 AHF CME credit hours.